提出一种对修正极大似然（modification of maximum likelihood）法的改进方法,记为IMML法。用于系统可靠性综合时进行系统等效成败型数据的折算,其准确度与CMSR法相同。既克服了L-M法的保守,又防止了MML法的冒进,并且消除了CMSR法在使...提出一种对修正极大似然（modification of maximum likelihood）法的改进方法,记为IMML法。用于系统可靠性综合时进行系统等效成败型数据的折算,其准确度与CMSR法相同。既克服了L-M法的保守,又防止了MML法的冒进,并且消除了CMSR法在使用上的限制,对高可靠零故障系统的可靠性评估具有重要意义。展开更多
The myelodysplastic/myeloproliferative neoplasms(MDS/MPNs) are a unique group of hematologic malignancies characterized by concomitant myelodysplastic and myeloproliferative features. According to the 2008 WHO classif...The myelodysplastic/myeloproliferative neoplasms(MDS/MPNs) are a unique group of hematologic malignancies characterized by concomitant myelodysplastic and myeloproliferative features. According to the 2008 WHO classification, the category includes atypical chronic myeloid leukemia(a CML), chronic myelomonocytic leukemia(CMML), juvenile myelomonocytic leukemia(JMML), MDS/MPN-unclassifiable(MDS/MPN-U), and the provisional entity refractory anemia with ring sideroblasts and thrombocytosis(RARS-T). Although diagnosis currently remains based on clinicopathologic features, the incorporation of nextgeneration platforms has allowed for the recent molecular characterization of these diseases which has revealed unique and complex mutational profiles that support their distinct biology and is anticipated to soon play an integral role in diagnosis,prognostication, and treatment. Future goals of research should include the development of disease-modifying therapies, and further genetic understanding of the category will likely form the foundation of these efforts.展开更多
文摘提出一种对修正极大似然（modification of maximum likelihood）法的改进方法,记为IMML法。用于系统可靠性综合时进行系统等效成败型数据的折算,其准确度与CMSR法相同。既克服了L-M法的保守,又防止了MML法的冒进,并且消除了CMSR法在使用上的限制,对高可靠零故障系统的可靠性评估具有重要意义。
文摘The myelodysplastic/myeloproliferative neoplasms(MDS/MPNs) are a unique group of hematologic malignancies characterized by concomitant myelodysplastic and myeloproliferative features. According to the 2008 WHO classification, the category includes atypical chronic myeloid leukemia(a CML), chronic myelomonocytic leukemia(CMML), juvenile myelomonocytic leukemia(JMML), MDS/MPN-unclassifiable(MDS/MPN-U), and the provisional entity refractory anemia with ring sideroblasts and thrombocytosis(RARS-T). Although diagnosis currently remains based on clinicopathologic features, the incorporation of nextgeneration platforms has allowed for the recent molecular characterization of these diseases which has revealed unique and complex mutational profiles that support their distinct biology and is anticipated to soon play an integral role in diagnosis,prognostication, and treatment. Future goals of research should include the development of disease-modifying therapies, and further genetic understanding of the category will likely form the foundation of these efforts.
